MSP Recovery Valuation

Is LIFW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LIFW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LIFW's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LIFW's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LIFW?

Key metric: As LIFW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LIFW. This is calculated by dividing LIFW's market cap by their current revenue.
What is LIFW's PS Ratio?
PS Ratio	0.3x
Sales	US$10.73m
Market Cap	US$10.16m

LIFW key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	121.8x
Enterprise Value/EBITDA	-24.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LIFW's PS Ratio compare to its peers?

The above table shows the PS ratio for LIFW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.5x
PMD Psychemedics	0.7x	n/a	US$13.8m
VVOS Vivos Therapeutics	1x	22.9%	US$14.1m
PAIY.Y Aesthetic Medical International Holdings Group	0.1x	n/a	US$12.0m
IDXG Interpace Biosciences	0.3x	n/a	US$11.7m
LIFW MSP Recovery	0.3x	n/a	US$10.2m

Price-To-Sales vs Peers: LIFW is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does LIFW's PS Ratio compare vs other companies in the US Healthcare Industry?

30 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$79.75b
CVS CVS Health	0.2x	4.6%	US$71.86b
COR Cencora	0.2x	6.4%	US$48.16b
CNC Centene	0.2x	5.5%	US$30.47b

30 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: LIFW is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is LIFW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LIFW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LIFW's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$93.6b

Operates as a health benefits company in the United States.

ELV

US$402.55

0.5%

-15.9%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.37

5.1%

-18.8%

electroCore

US$64.0m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

2.5%

101.6%